{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-001610","form_type":"8-K","ticker":"UG","cik":"0000101295","company_name":"UNITED GUARDIAN INC","filed_at":"2025-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.694962+00:00","generated_at":"2026-05-24T07:53:05.581662+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"United-Guardian FY 2024 net sales +12% to $12.18M; EPS $0.71 vs $0.56","bullets":["Net income $3.25M ($0.71 per share) vs $2.58M ($0.56) in FY 2023.","Cosmetics ingredients sales surged 32%; medical lubricants up 16%.","Pharmaceutical sales fell 5% due to Renacidin supply disruption into Q1 2024.","Management expects Renacidin sales to recover to prior levels in 2025.","Growth driven by increased demand from largest distributor and Chinese accounts."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-001610","json":"https://secwatch.observer/filing/0001171843-25-001610.json","markdown":"https://secwatch.observer/filing/0001171843-25-001610.md","text":"https://secwatch.observer/filing/0001171843-25-001610.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/101295/000117184325001610/0001171843-25-001610-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/101295/000117184325001610/f8k_032025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T07:53:05.581662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}